Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy

Breast cancer is a major killer of women's health worldwide. While breast cancer is thought to have lower immunogenicity compared with other solid tumors, combination therapy is able to improve the immunogenicity of the tumor and sensitize breast cancer cells to immunotherapy. Immunotherapy rep...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2022-01, Vol.11, p.724424-724424
Main Authors: Chen, Fei, Chen, Naifei, Gao, Yangyang, Jia, Lin, Lyu, Zheng, Cui, Jiuwei
Format: Article
Language:English
Subjects:
breast cancer
immune checkpoint inhibitor
immunotherapy
Oncology
PD-1
PD-L1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer is a major killer of women's health worldwide. While breast cancer is thought to have lower immunogenicity compared with other solid tumors, combination therapy is able to improve the immunogenicity of the tumor and sensitize breast cancer cells to immunotherapy. Immunotherapy represented by immune checkpoint inhibitors (ICIs) has been largely explored in the field of breast cancer, including both early and advanced disease. Immunotherapy for triple-negative breast cancer (TNBC) has been the most studied, and the PD-L1 inhibitor atezolizumab combined with nab-paclitaxel has been used in the first-line treatment of TNBC. Immunotherapeutic data for human epidermal growth factor receptor-positive and hormone receptor-positive breast cancer are also accumulating. This review summarizes the clinical trial data of ICIs or ICI-containing therapies in different types and stages of breast cancer.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.724424